There are 360 resources available
94P - Does hyperprogressive disease predict poor survival?
Presenter: Gulin Alkan
Session: Poster Display
95P - A phase II study of combination of H101 (a recombinant human adenovirus type 5) and nivolumab for advanced hepatocellular carcinoma (HCC) after systemic therapy failure
Presenter: jing xie
Session: Poster Display
96P - Long-term outcomes after initial disease progression with anti-PD-1 in melanoma
Presenter: Kimberly Loo
Session: Poster Display
97P - Toxicity of bispecific antibody glofitamab in patients with aggressive B-cell non-Hodgkin lymphoma in real clinical practice
Presenter: Liudmila Fedorova
Session: Poster Display
98P - First-line atezolizumab/durvalumab plus platinumÐetoposide combined with radiotherapy in extensive-stage small-cell lung cancer
Presenter: Anhui Shi
Session: Poster Display
99P - Sintilimab plus nab-paclitaxel in platinum-refractory head and neck squamous cell carcinoma: a phase 2 trial
Presenter: Shengyu Zhou
Session: Poster Display
100P - Immunotherapy around the clock: impact on stage IV melanoma
Presenter: Lisa Goncalves
Session: Poster Display